NovoCure shares preliminary 2025 results update

NovoCure Limited filed a current report to disclose that on January 12, 2026 it issued a press release with certain preliminary financial results and other information for the quarter and year ended December 31, 2025.

Rhea-AI Filing Summary

NovoCure Limited filed a current report to disclose that on January 12, 2026 it issued a press release with certain preliminary financial results and other information for the quarter and year ended December 31, 2025. The report explains that the figures in the press release are unaudited, preliminary, based on the company’s good faith estimates, and remain subject to completion of its financial closing procedures and final adjustments, so actual results may differ materially. The press release is furnished as Exhibit 99.1 and the company specifies that this information is being furnished under the securities laws rather than filed for liability purposes.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NovoCure (NVCR) report in its latest 8-K filing?

NovoCure Limited reported that it issued a press release on January 12, 2026 providing certain preliminary financial results and other information for the quarter and year ended December 31, 2025.

Which period do NovoCure's preliminary financial results in this 8-K cover?

The preliminary financial results and related information cover the quarter and the full year ended December 31, 2025.

Are the financial figures disclosed by NovoCure in this update audited?

No. The company states that the financial data are unaudited, preliminary, based on its good faith estimates, and subject to completion of financial closing procedures and final adjustments.

Where can investors find the detailed preliminary results from NovoCure?

The detailed preliminary results are contained in the press release furnished as Exhibit 99.1 to the report, titled "Press Release of NovoCure Limited, dated January 12, 2026."

Does NovoCure treat the preliminary results in this report as filed or furnished?

NovoCure states that the information in Item 2.02 is being furnished, not filed, for purposes of the Securities Exchange Act and will only be incorporated into other filings if specifically referenced.

Who signed NovoCure's 8-K containing the preliminary 2025 results?

The report was signed on behalf of NovoCure Limited by Christoph Brackmann, who is identified as the company’s Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 07:00 AM Learn about SEC filing dates

0001645113false00016451132026-01-012026-01-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

January 12, 2026

Date of Report (date of earliest event reported)

NovoCure Limited

(Exact name of registrant as specified in its charter)

Jersey			001-37565						98-1057807
(State or other jurisdiction of incorporation or organization)			(Commission File Number)						(I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street			St. Helier			Jersey			JE2 4UF
(Address of Principal Executive Offices)									(Zip Code)

+44 (0) 15 3475 6700

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Ordinary Shares, no par value			NVCR			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

o

Item 2.02     Results of Operations and Financial Condition.

On January 12, 2026, NovoCure Limited ( the "Company") issued a press release announcing certain preliminary financial results and providing certain other information for the quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 (the “Press Release”).

The financial data contained therein are unaudited, preliminary, based upon the Company’s good faith estimates and subject to completion of the Company’s financial closing procedures. While the Company expects that its final financial results for the quarter and year ended December 31, 2025, following the completion of its financial closing procedures, will generally be consistent with the information provided in the Press Release, the Company’s actual results may differ materially from these estimates as a result of the completion of its financial closing procedures for the quarter and year ended December 31, 2025, as well as final adjustments and other developments that may arise between now and the time that its financial results for the quarter and year ended December 31, 2025 are finalized.

The information contained in item 2.02 of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.			Description
99.1			Press Release of NovoCure Limited, dated January 12, 2026
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovoCure Limited

(Registrant)

Date: January 12, 2026

By: /s/ Christoph Brackmann

Name: Christoph Brackmann

Title: Chief Financial Officer